Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-H0731 plus entecavir vs entecavir alone in viremic HBeAg-positive chronic hepatitis B (Phase 2a)
2018-002042-36Phase 2Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ABI-H0731 + entecavir with Placebo + entecavir (2 arms). Primary endpoints: Change in mean log10 HBV DNA at Week 12 and Change in mean log10 HBV DNA at Week 24. Started Sep 2018; status: completed.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2018-002042-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002042-36.